Analysis of NOAC Plasma Levels: Are Palliative Care Patients with Atrial Fibrillation and Metastatic Cancer adequately Anticoagulated?

Analysis of NOAC Plasma Levels: Are Palliative Care Patients with Atrial Fibrillation and Metastatic Cancer adequately Anticoagulated? - PALL-NOAC

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00040298

Enrollment

100

Registered

2026-05-21

Start date

2026-06-15

Completion date

Unknown

Last updated

2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Z51.5

Interventions

Group 1: Study participants are recruited during a consultation conducted by the Palliative Medicine Service (PMD) and the study team from the Department of Palliative Medicine at University Hospital

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients with metastatic solid tumor disease in specialized palliative care

Exclusion criteria

Exclusion criteria: - Concomitant therapy with vitamin K antagonists, heparins, argatroban, hirudin - Inability to provide consent

Design outcomes

Primary

Measure	Time frame
Evaluation of the proportion of patients with a NOAC medication whose plasma levels are within the target range.	—

Secondary

Measure	Time frame
Correlation between plasma levels of NOACs and clinical events such as strokes and TIAs.	—

Countries

Germany

Contacts

Public ContactBaicy Mathew

Palliativmedizin der Universitätsmedizin Essen

baicy.mathew@uk-essen.de+492017237264

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Jun 11, 2026